GAVI program money "paid for non-existent vaccinations"

12 January 2009

An Institute for Health Metrics and Evaluation report published in The Lancet alleges that only 7.4 million children, out of almost 14 million  claimed by the GAVI Alliance, had been immunized against diphteria,  pertussis (whooping cough) and tetanus (DPT3 vaccine) under a program  operated by the aid group.

Philip Stevens, the health program director of the International Policy  Network, a London-based think-tank specializing in development issues,  told the Associated Press: "with the unprecedented billions given by the  international community, there is no excuse for these poor coverage  rates." He added: "one has to wonder where the money has gone, hopefully  not into Swiss bank accounts."

In a statement, the Geneva, Switzerland-based group, has responded to  claims made by the IHME, by inviting its head, Chris Murray, to join a  task force to evaluate the quality of GAVI's own figures, which are  based on World Health Organization- and UNICEF-validated data. A  spokesman for the GAVI Alliance told the Marketletter that the team was  formed in early 2008.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight